Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,041

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial

Open access
Mehanna, Hisham, Robinson, Max, Hartley, Andrew, Kong, Anthony, Foran, Bernadette, Fulton-Lieuw, Tessa, Dalby, Matthew, Mistry, Pankaj, Sen, Mehmet, O'Toole, Lorcan, Al Booz, Hoda, Dyker, Karen, Moleron, Rafael, Whitaker, Stephen, Brennan, Sinead, Cook, Audrey, Griffin, Matthew, Aynsley, Eleanor, Rolles, Martin, De Winton, Emma, Chan, Andrew, Srinivasan, Devraj, Nixon, Ioanna, Grumett, Joanne, Leemans, C René, Buter, Jan, Henderson, Julia, Harrington, Kevin, McConkey, Christopher, Gray, Alastair, Dunn, Janet, Moleron, Rafael, McArdle, Orla, Dyker, Karen, Al Booz, Hoda, O'Toole, Lorcan, Cook, Audrey, Husband, David, Loo, Vivienne, Soe, Win, Aynsley, Eleanor, Sridhar, Thiagarajan, Jankowska, Petra, Joseph, Mano, Geropantas, Konstantinos, Vaidya, Deepali, Griffin, Matthew, Hartley, Andrew, Vijayan, Rengarajan, Hwang, David, Harrington, Kevin, Pettit, Laura, Whitaker, Stephen, De Winton, Emma, Rolles, Martin, Brennan, Sinéad, Sen, Mehmet, Mendes, Ruheena, Forster, Martin, Chan, Andrew, Evans, Mererid, Buter, Jan, Srinivasan, Devraj, Foran, Bernie, Nankivell, Paul, Bryant, Jennifer, Sharma, Neil, Spruce, Rachel, Brooks, Jill, Batis, Nikos, Roques, Tom, Bidmead, Margaret, Yang, Huiqi, Nutting, Christopher, Tyler, Justine, Henderson, Julia, Baines, Helen, Gasnier, Anne, Miles, Elizabeth, Clark, Catharine, Evans, Mererid·2019·The Lancet
DOI 10.1016/s0140-6736(18)32752-1
Open this paper in CoChat — free account

Abstract

Background The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity of standard cisplatin treatment, but no randomised evidence exists for the efficacy of this strategy. Methods We did an open-label randomised controlled phase 3 trial at 32 head and neck treatment centres in Ireland, the Netherlands, and the UK, in patients aged 18 years or older with HPV-positive low-risk oropharyngeal cancer (non-smokers or lifetime smokers with a smoking history of <10 pack-years). Eligible patients were randomly assigned (1:1) to receive, in addition to radiotherapy (70 Gy in 35 fractions), either intravenous cisplatin (100 mg/m 2 on days 1, 22, and 43 of radiotherapy) or intravenous cetuximab (400 mg/m 2 loading dose followed by seven weekly infusions of 250 mg/m 2 ). The primary outcome was overall severe (grade 3–5) toxicity events at 24 months from the end of treatment. The primary outcome was assessed by intention-to-treat and per-protocol analyses. This trial is registered with the ISRCTN registry, number ISRCTN33522080. Findings Between Nov 12, 2012, and Oct 1, 2016, 334 patients were recruited (166 in the cisplatin group and 168 in the cetuximab group). Overall (acute and late) severe (grade 3–5) toxicity did not differ significantly between treatment groups at 24 months (mean number of events per patient 4·8 [95% CI 4·2–5·4] with cisplatin vs 4·8 [4·2–5·4] with cetuximab; p=0·98). At 24 months, overall all-grade toxicity did not differ significantly either (mean number of events per patient 29·2 [95% CI 27·3–31·0] with cisplatin vs 30·1 [28·3–31·9] with cetuximab; p=0·49). However, there was a significant difference between cisplatin and cetuximab in 2-year overall survival (97·5% vs 89·4%, hazard ratio 5·0 [95% CI 1·7–14·7]; p=0·001) and 2-year recurrence (6·0% vs 16·1%, 3·4 [1·6–7·2]; p=0·0007). Interpretation Compared with the standard cisplatin regimen, cetuximab showed no benefit in terms of reduced toxicity, but instead showed significant detriment in terms of tumour control. Cisplatin and radiotherapy should be used as the standard of care for HPV-positive low-risk patients who are able to tolerate cisplatin. Funding Cancer Research UK.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)32752-1

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 1,041

Metadata

Authors
Mehanna, H., Robinson, M., Hartley, A., Kong, A., Foran, B., Fulton-Lieuw, T., Dalby, M., Mistry, P., Sen, M., O'Toole, L., Al Booz, H., Dyker, K., Moleron, R., Whitaker, S., Brennan, S., Cook, A., Griffin, M., Aynsley, E., Rolles, M., De Winton, E., Chan, A., Srinivasan, D., Nixon, I., Grumett, J., Leemans, C. R., Buter, J., Henderson, J., Harrington, K., McConkey, C., Gray, A., Dunn, J., Moleron, R., McArdle, O., Dyker, K., Al Booz, H., O'Toole, L., Cook, A., Husband, D., Loo, V., Soe, W., Aynsley, E., Sridhar, T., Jankowska, P., Joseph, M., Geropantas, K., Vaidya, D., Griffin, M., Hartley, A., Vijayan, R., Hwang, D., Harrington, K., Pettit, L., Whitaker, S., De Winton, E., Rolles, M., Brennan, S., Sen, M., Mendes, R., Forster, M., Chan, A., Evans, M., Buter, J., Srinivasan, D., Foran, B., Nankivell, P., Bryant, J., Sharma, N., Spruce, R., Brooks, J., Batis, N., Roques, T., Bidmead, M., Yang, H., Nutting, C., Tyler, J., Henderson, J., Baines, H., Gasnier, A., Miles, E., Clark, C., & Evans, M.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-01
Volume
393
Issue
10166
Pages
51-60
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(18)32752-1
OpenAlex
W2901385432
Cited by
1,041
References
21
FWCI
94.45
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)32752-1
The paper
Mehanna, H., Robinson, M., Hartley, A., Kong, A., Foran, B., Fulton-Lieuw, T., Dalby, M., Mistry, P., Sen, M., O'Toole, L., Al Booz, H., Dyker, K., Moleron, R., Whitaker, S., Brennan, S., Cook, A., Griffin, M., Aynsley, E., Rolles, M., . . . Evans, M. (2019). Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)32752-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.